Form 4: DMII Sponsor Adjusts Holdings, Acquires Units

Drugs Made In America Acquisition II LLC, a 10% owner, reported significant changes in its beneficial ownership of ordinary shares and derivative securities, including an acquisition of private units and transfers to officers, directors, and accredited investors.

Summary

• Drugs Made In America Acquisition II LLC, the sponsor and a 10% owner of Drugs Made In America Acquisition II Corp. (DMII), reported several transactions on September 26, 2025.
• The reporting person acquired 700,000 private units, each consisting of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination.
• These private units were purchased at $10 per unit, totaling an aggregate purchase price of $7,000,000.
• Following this acquisition, the reporting person beneficially owned 15,075,000 ordinary shares.
• The reporting person transferred 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
• An additional 7,966,667 ordinary shares were transferred to a number of accredited investors for consideration ranging from no consideration to $1.50 per share.
• After all reported transactions, the reporting person's direct beneficial ownership of ordinary shares stands at 6,708,333.
• The reporting person also beneficially owns 700,000 rights to receive ordinary shares, which convert automatically into ordinary shares upon the completion of the Issuer's initial business combination.

Sentiment

Score: 5

Explanation: The filing presents a mixed picture. The sponsor's $7 million investment in private units is a positive sign of commitment. However, the subsequent transfer of a large number of shares (over 8 million) to officers, directors, and accredited investors for low or no consideration could be viewed negatively by public shareholders due to potential dilution, balancing the overall sentiment to neutral.

Positives

• The sponsor, Drugs Made In America Acquisition II LLC, invested $7,000,000 to acquire 700,000 private units, demonstrating continued commitment to the Issuer.
• The acquisition of private units by the sponsor aligns their interests with future company performance, as the rights convert upon a business combination.

Negatives

• A significant number of ordinary shares (400,000) were transferred to officers and directors for no consideration, potentially diluting existing shareholder value.
• An additional 7,966,667 ordinary shares were transferred to accredited investors for consideration ranging from no consideration to $1.50 per share, which is significantly below the $10 per unit price paid by the sponsor for its private units, suggesting potential dilution or favorable terms for these investors.
• The total beneficial ownership of ordinary shares by the sponsor decreased from 15,075,000 to 6,708,333 following the transfers.

Risks

• Potential dilution for public shareholders due to the transfer of a large number of ordinary shares (8,366,667 shares in total) to officers, directors, and accredited investors for low or no consideration.
• The valuation of shares transferred to accredited investors at up to $1.50 per share, compared to the $10 per unit price paid by the sponsor, could indicate a discrepancy in perceived value or preferential treatment.

Future Outlook

The rights to receive ordinary shares held by the reporting person will convert automatically into ordinary shares upon the completion of the Issuer's initial business combination.

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) sponsor (Drugs Made In America Acquisition II LLC) reporting its initial equity holdings and subsequent distributions to key personnel and early investors. The structure of private units (shares plus rights) and the eventual conversion upon a business combination are standard for SPACs. The transfers of shares to officers, directors, and accredited investors are common practices for SPAC sponsors to incentivize management and distribute founder shares.

Comparison to Industry Standards

• The acquisition of private units by the sponsor at $10 per unit is standard for SPACs, where units typically trade at this price pre-business combination.
• The transfer of shares to officers and directors for no consideration is a common practice in SPACs, often representing "founder shares" or "promote" given to the management team for their efforts in identifying and executing a business combination.
• The transfer of shares to accredited investors for low or no consideration is also typical for SPACs, often part of the initial structuring or early investor arrangements, which can include "at-risk" capital or early support.
• The structure of rights converting into a fraction of an ordinary share upon business combination is a common feature in SPAC private units.

Related Party Transactions

• Transfer of 400,000 ordinary shares from the reporting person (sponsor) to certain of the Issuer's officers and directors for no consideration.
• Transfer of 7,966,667 ordinary shares from the reporting person (sponsor) to a number of accredited investors for consideration ranging from no consideration to $1.50 per share.

Stakeholder Impact

• Shareholders: Potential dilution from the significant transfer of shares to officers, directors, and accredited investors for low or no consideration.
• Officers and Directors: Benefited from receiving 400,000 ordinary shares for no consideration, aligning their interests with the company's performance.
• Accredited Investors: Benefited from receiving 7,966,667 ordinary shares for consideration ranging from no consideration to $1.50 per share, potentially at a favorable valuation.

Next Steps

• Consummation of an initial business combination, which will trigger the conversion of the rights to receive ordinary shares.

Key Dates

Keywords

DMII, Form 4, insider transaction, beneficial ownership, SPAC, sponsor, share transfer, private units, equity, corporate governance, investment